Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 0563 2019/20 CAR T-Cell Therapies

Home > FOI Requests > Patient Data > FOI 0563 2019/20 CAR T-Cell Therapies

January 15, 2020

Last updated: January 15, 2020

Freedom of Information Request: 0563 2019/20

  1. With regards to the usage of Chimeric Antigen Receptor T-Cell (CAR T-cell) therapies. Could you please provide me with the following numbers of patients treated with an infusion of Chimeric Antigen Receptor T-Cell (CAR T-cell) therapies since 1st September 2019 with the following drugs and where possible please could you split by the indication for which the drug was provided?

 

Please note that this data applies to Queen Elizabeth Hospital Birmingham only. CAR-T is currently not undertaken at the Heartlands, Good Hope and Solihull sites.

Number of patients treated B-cell acute lymphoblastic leukaemia (ALL) Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Primary mediastinal large B-cell lymphoma (PMBCL) All Indications

(Total)
Yescarta (axicabtagene ciloleucel)  Not Applicable 7 0  7
Kymriah (tisagenlecleucel)  0  3  0  3

 

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.